Viravaxx’ SARS-CoV-2 blocking Antibody Test informs if a COVID-19 convalescent patient or vaccinated person has developed neutralizing antibodies which block the interaction of RBD with ACE2. Viravaxx used its proprietary SARS-CoV-2 blocking Antibody Test to analyze serum samples from patients who recovered from COVID-19. The findings helped to understand the requirements for a vaccine to induce “sterilizing immunity”. This is of utmost importance since a significant percentage of COVID-19 convalescent patients do not produce antibodies capable of completely blocking RBD binding to the receptor protein ACE2. Recently generated pre-clinical data suggest that Viravaxx’ vaccine candidate is able to induce sterilizing immunity also in those patients who develop RBD-ACE2 blocking antibodies with only suboptimal capacity.
Dr. Helmut Brunar
+43 664 415 9511